Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
$172.19
+0.9%
$153.65
$118.73
$173.62
$9.85B1.02405,793 shs366,525 shs
HealthEquity, Inc. stock logo
HQY
HealthEquity
$87.98
-1.5%
$96.01
$73.84
$116.65
$7.72B0.54943,650 shs872,967 shs
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
$92.50
+0.8%
$115.37
$73.92
$225.00
$2.71B1.221.69 million shs1.25 million shs
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
$131.87
$131.87
$70.90
$131.98
$14.05B0.691.57 million shsN/A
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
+0.88%+1.88%+16.52%+17.50%+16.22%
HealthEquity, Inc. stock logo
HQY
HealthEquity
-1.51%-1.19%-8.12%-12.87%+15.28%
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
+0.66%-0.59%-29.24%-32.95%-50.85%
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
0.00%0.00%0.00%0.00%+78.49%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
4.4098 of 5 stars
1.44.03.34.83.02.51.3
HealthEquity, Inc. stock logo
HQY
HealthEquity
4.3565 of 5 stars
4.53.00.00.03.62.51.9
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
4.9391 of 5 stars
4.34.00.04.83.91.71.9
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
0.8786 of 5 stars
1.10.00.04.50.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
2.83
Moderate Buy$171.00-0.69% Downside
HealthEquity, Inc. stock logo
HQY
HealthEquity
3.00
Buy$118.5534.74% Upside
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
2.54
Moderate Buy$165.6279.04% Upside
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
2.20
Hold$118.00-10.52% Downside

Current Analyst Ratings Breakdown

Latest HQY, ENSG, INSP, and ITCI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/15/2025
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Perform ➝ Market Perform$116.00 ➝ $97.00
8/14/2025
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$185.00 ➝ $195.00
8/5/2025
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$270.00 ➝ $150.00
8/5/2025
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$174.00 ➝ $101.00
8/5/2025
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$270.00 ➝ $230.00
8/5/2025
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$215.00 ➝ $180.00
8/5/2025
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$233.00 ➝ $150.00
8/5/2025
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$190.00 ➝ $125.00
8/5/2025
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetHold ➝ Hold$175.00 ➝ $140.00
8/5/2025
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral$195.00 ➝ $110.00
8/5/2025
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Sector Weight
(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
$4.26B2.33$6.64 per share25.93$35.03 per share4.92
HealthEquity, Inc. stock logo
HQY
HealthEquity
$1.20B6.34$4.20 per share20.95$24.40 per share3.61
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
$802.80M3.41$1.72 per share53.70$22.92 per share4.04
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
$680.50M20.64N/AN/A$6.15 per share21.44
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
$297.97M$5.5131.2527.911.966.99%16.92%6.72%10/23/2025 (Estimated)
HealthEquity, Inc. stock logo
HQY
HealthEquity
$96.70M$1.3764.2230.981.389.80%11.01%6.77%9/2/2025 (Estimated)
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
$53.51M$1.7353.4728.732.866.17%10.38%8.93%11/3/2025 (Estimated)
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
-$139.67M-$0.73N/A694.05N/A-14.07%-9.93%-8.38%N/A

Latest HQY, ENSG, INSP, and ITCI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/2/2025Q2 2026
HealthEquity, Inc. stock logo
HQY
HealthEquity
$0.92N/AN/AN/A$320.68 millionN/A
8/4/2025Q2 2025
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
$0.22$0.45+$0.23-$0.12$214.50 million$217.09 million
7/24/2025Q2 2025
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
$1.54$1.59+$0.05$1.44$1.22 billion$1.23 billion
6/3/2025Q1 2026
HealthEquity, Inc. stock logo
HQY
HealthEquity
$0.81$0.97+$0.16$0.61$322.25 million$330.80 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
$0.250.15%N/A4.54%18 Years
HealthEquity, Inc. stock logo
HQY
HealthEquity
N/AN/AN/AN/AN/A
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
N/AN/AN/AN/AN/A
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
N/AN/AN/AN/AN/A

Latest HQY, ENSG, INSP, and ITCI Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/19/2025
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
Quarterly$0.06250.16%6/30/20256/30/20257/31/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
0.07
1.41
1.41
HealthEquity, Inc. stock logo
HQY
HealthEquity
0.50
4.06
4.06
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
N/A
6.14
4.84
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
N/A
7.66
7.51

Institutional Ownership

CompanyInstitutional Ownership
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
96.12%
HealthEquity, Inc. stock logo
HQY
HealthEquity
99.55%
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
94.91%
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
92.33%

Insider Ownership

CompanyInsider Ownership
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
3.90%
HealthEquity, Inc. stock logo
HQY
HealthEquity
1.50%
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
4.10%
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
2.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
39,30057.70 million55.45 millionOptionable
HealthEquity, Inc. stock logo
HQY
HealthEquity
3,12086.47 million85.18 millionOptionable
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
1,24629.57 million28.36 millionOptionable
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
560106.52 million103.56 millionOptionable

Recent News About These Companies

JnJ closes Intra-Cellular Therapies acquisition
Intra-Cellular Therapies
Intra-Cellular downgraded to Neutral from Outperform at Mizuho

New MarketBeat Followers Over Time

Media Sentiment Over Time

The Ensign Group stock logo

The Ensign Group NASDAQ:ENSG

$172.19 +1.51 (+0.88%)
Closing price 08/27/2025 04:00 PM Eastern
Extended Trading
$172.17 -0.02 (-0.01%)
As of 08/27/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The Ensign Group, Inc. provides skilled nursing, senior living, and rehabilitative services. It operates through two segments: Skilled Services and Standard Bearer. The company's Skilled Services segment engages in the operation of skilled nursing facilities and rehabilitation therapy services for patients with chronic conditions, prolonged illness, and the elderly; and offers nursing facilities including specialty care, such as on-site dialysis, ventilator care, cardiac, and pulmonary management, as well as standard services comprising room and board, special nutritional programs, social services, recreational activities, entertainment, and other services. Its Standard Bearer segment is comprised of selected real estate properties owned by Standard Bearer and leased to skilled nursing and senior living operators. In addition, the company provides ancillary services consisting of digital x-ray, ultrasound, electrocardiograms, sub-acute services, dialysis, respiratory, and long-term care pharmacy and patient transportation to people in their homes or at long-term care facilities, as well as mobile diagnostics. It operates in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. The company was incorporated in 1999 and is based in San Juan Capistrano, California.

HealthEquity stock logo

HealthEquity NASDAQ:HQY

$87.98 -1.35 (-1.51%)
Closing price 08/27/2025 04:00 PM Eastern
Extended Trading
$88.00 +0.02 (+0.02%)
As of 08/27/2025 07:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts. It also provides investment platform; and online-only automated investment advisory services through Advisor, a Web-based tool. In addition, the company offers flexible spending accounts; health reimbursement arrangements; and Consolidated Omnibus Budget Reconciliation Act continuation services, as well as administers pre-tax commuter benefit programs. It serves clients through a direct sales force; benefits brokers and advisors; and a network of health plans, benefits administrators, benefits brokers and consultants, and retirement plan record-keepers. HealthEquity, Inc. was incorporated in 2002 and is based in Draper, Utah.

Inspire Medical Systems stock logo

Inspire Medical Systems NYSE:INSP

$92.50 +0.75 (+0.82%)
Closing price 08/27/2025 03:59 PM Eastern
Extended Trading
$90.50 -2.00 (-2.16%)
As of 08/27/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.

Intra-Cellular Therapies stock logo

Intra-Cellular Therapies NASDAQ:ITCI

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.